Phase I Multi-Center Study of Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cervical cancer; Vulvovaginal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 18 Jul 2018 Status changed from not yet recruiting to recruiting.
- 21 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.